Physician profile
Scott Michael Spector
NPI 1073553707
$23,346.78
in general payments reported to CMS, 2019-2025
36 companies · $3,366 in 2025
The $3,366 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,417 · 2020: $1,287 · 2021: $4,719 · 2022: $1,333 · 2023: $1,372 · 2024: $1,853 · 2025: $3,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,513 · Grant: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,512.61 |
| Grant | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $6,573.32 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $3,732.27 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Eyevance Pharmaceuticals LLC | $1,886.96 | 2019-2023 | Flarex |
| Abbvie INC. | $1,434.48 | 2022-2025 | Durysta, Lumigan |
| Harrow Eye, LLC | $1,312.07 | 2023-2025 | Tobradex St, Iheezo |
| Alcon Vision LLC | $1,306.00 | 2019-2025 | Tryptyr, Clareon, Rocklatan |
| Sun Pharmaceutical Industries INC. | $1,025.26 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $631.69 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $622.34 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Allergan, INC. | $603.48 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $508.31 | 2023-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Carl Zeiss Meditec, INC. | $439.01 | 2019-2020 | |
| Rxsight INC | $398.89 | 2021-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $390.19 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $342.37 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $326.31 | 2020-2025 | Idosetr |
| Omeros Corporation | $250.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $248.69 | 2019-2023 | |
| Eyepoint US, INC. | $232.06 | 2019-2020 | |
| Oyster Point Pharma, INC. | $222.67 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $160.24 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $127.84 | 2019-2020 | |
| Ivantis, INC | $105.26 | 2021 | |
| Shire North American Group INC | $76.45 | 2019 | |
| Biotissue Holdings INC. | $58.28 | 2025 | |
| Amgen INC. | $52.27 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $49.17 | 2024-2025 | Dextenza |
| Carl Zeiss Meditec USA, INC. | $43.19 | 2024 | Artevo 800 |
| New World Medical,INC. | $39.20 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $28.96 | 2019-2020 | |
| Lkc Technologies, INC. | $28.23 | 2025 | |
| Optos, INC. | $21.52 | 2019 | |
| Thea Pharma INC. | $20.94 | 2025 | Iyuzeh |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $20.33 | 2025 | |
| Coopervision INC. | $14.46 | 2019 | |
| Akorn, INC. | $14.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.